• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.

    8/6/25 6:55:46 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Cullinan Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share (the "Shares")

    (Title of Class of Securities)


    230031106

    (CUSIP Number)


    07/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,511,191.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,511,191.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,511,191.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 59,014,667 Shares outstanding as of April 30, 2025 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on May 8, 2025). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on August 6, 2025.


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,511,191.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,511,191.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,511,191.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,511,191.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,511,191.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,511,191.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    497,935.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    497,935.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    497,935.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    497,935.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    497,935.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    497,935.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    497,935.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    497,935.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    497,935.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    230031106


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,009,126.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,009,126.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,009,126.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cullinan Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    One Main Street, Suite 1350 Cambridge, MA, 02142
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), Citadel CEMF Investments Ltd., a Cayman Islands limited company ("CCIL"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM and CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of the Reporting Persons is 830 Brickell Plaza, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share (the "Shares")
    (e)CUSIP No.:

    230031106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 2,511,191 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 497,935 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 497,935 Shares. 4. Mr. Griffin may be deemed to beneficially own 3,009,126 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 4.3% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.8% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.8% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 5.1% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 2,511,191 2. Citadel Securities LLC: 497,935 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 497,935 4. Mr. Griffin: 3,009,126

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 2,511,191 2. Citadel Securities LLC: 497,935 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 497,935 4. Mr. Griffin: 3,009,126

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:08/06/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:08/06/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $CGEM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEM

    DatePrice TargetRatingAnalyst
    6/11/2025$22.00Buy
    Stifel
    10/24/2024$30.00Buy
    UBS
    5/1/2024$40.00Buy
    Stifel
    4/15/2024Outperform
    William Blair
    2/15/2024$30.00Outperform
    Wedbush
    6/15/2023Outperform
    TD Cowen
    11/21/2022$20.00Buy
    BTIG Research
    More analyst ratings

    $CGEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., to its Board of Directors CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focu

    8/7/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

    Updated efficacy data will be presented from the REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab Preliminary findings to be shared from the cohort of patients with uncommon non-ex20ins EGFR mutations enrolled in the REZILIENT2 trial of zipalertinibPRINCETON, N.J. and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of Lung Cancer's

    7/22/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

    Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig,

    6/4/25 4:02:00 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Doyle Mittie

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    8/8/25 5:30:07 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Allen Andrew R

    3 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    8/8/25 5:30:05 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Doyle Mittie

    3 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    8/8/25 5:30:03 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Cullinan Therapeutics with a new price target

    Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00

    6/11/25 8:09:08 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Cullinan Therapeutics with a new price target

    UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

    10/24/24 6:18:20 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Cullinan Management with a new price target

    Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00

    5/1/24 6:23:49 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    SEC Filings

    View All

    SEC Form 10-Q filed by Cullinan Therapeutics Inc.

    10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    8/7/25 7:07:10 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

    8/7/25 7:04:20 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Cullinan Therapeutics Inc.

    SCHEDULE 13G - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    8/6/25 6:55:46 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Leadership Updates

    Live Leadership Updates

    View All

    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

    CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast

    4/29/24 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

    CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012.   Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his

    11/2/22 8:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

    CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a

    8/15/22 4:57:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 5:05:22 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/14/24 4:24:39 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

    SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

    11/12/24 2:23:54 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEM
    Financials

    Live finance-specific insights

    View All

    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO 2025 and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC 2025 WCLC and ESMO Congress 2025 Company appoints Mittie Doyle, M.D., and Andrew Allen, M.D., Ph.D., to its Board of Directors CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focu

    8/7/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

    Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of diseases while maintaining cash runway into 2028 Company to host conference call today at 4:30 pm ET CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into an agreement with Genrix Bio for a global (ex-Greater China), all indication, exclusive license to velinotamig,

    6/4/25 4:02:00 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

    Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first

    5/8/25 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care